iMPCs: Cell Reprogrammers Take Aim at Liver Disease
Posted on by Dr. Francis Collins
Over the past few years, researchers have learned how to reprogram skin or blood cells into induced pluripotent stem cells (iPSCs), which have the ability to differentiate into heart, nerve, muscle, and many other kinds of cells. But it’s proven a lot more tricky to coax iPSCs (as well as human embryonic stem cells) to differentiate into mature, fully functional liver cells.
Now, NIH-funded researchers at the University of California, San Francisco (UCSF) and the Gladstone Institutes appear to have overcome this problem. They have developed a protocol that transforms human skin cells into mature liver cells that not only function normally in a lab dish, but proliferate after they’ve been transplanted into mice that model human liver failure . This ability to proliferate is a hallmark of normal liver cells—and the secret to the liver’s astounding capacity to regenerate after infection or injury.
This work is significant because currently the only treatment for liver failure is a liver transplant, which carries the risk of organ rejection and infections related to the immune-suppressive drugs used to prevent such rejection. More than 16,000 Americans are currently on the waiting list for liver transplants, and thousands die each year before a donated organ can be found. While this report is just an early step, it holds the promise of providing new liver cells from a patient’s own skin cells. This could help many people with liver disease without the use of surgery and immune-suppressive drugs, thereby freeing up the limited supply of donated livers for those who can’t be helped by any other method.
So, how did the San Francisco team pull off their feat? Using three of the four genes used to generate iPSCs, they reprogrammed skin cells back to an intermediate state that lies somewhere between an embryonic-like, undifferentiated stem cell and a mature, differentiated cell. This new type of cell, called induced multipotent progenitor cells (iMPCs), are not as versatile as iPSCs, but they do make it much easier to generate cells from the layer called endoderm, and, subsequently, liver cells. (For those of you who aren’t experts in developmental biology, the endoderm is the innermost of an early-stage embryo’s three layers of cells, and, among other things, it gives rise to the liver, pancreas, and bladder.)
Another advantage of iMPCs is that they may be somewhat safer for use in cell-based therapies. One risk associated with iPSC technology is that differentiated cells intended for therapy might occasionally be contaminated with undifferentiated iPSCs, which are capable of producing rapidly growing but benign tumors called teratomas if transplanted into the body. This should be less of an issue with iMPCs, because they never reach a fully undifferentiated state.
To begin the reprogramming process, the researchers first used viral vectors to insert the OCT4, SOX2, and KLF4 genes into the DNA of human skin cells growing in a lab dish. After three days—once the skin cells had begun the reprogramming process—the researchers began adding a series of liver-specific growth factors and chemicals to the dish to encourage the iMPCs to differentiate into liver cells. After three months, the lab-grown liver cells—which closely resembled liver progenitor cells, but were not yet fully mature—were transplanted into a strain of immune-deficient mice that serves as a model of human liver failure.
To test whether the transplanted cells had “taken,” the researchers drew blood from the mice and measured the levels of human albumin, a protein secreted by mature liver cells. After two months, human albumin became detectable in the mice’s blood and the levels increased continuously for more than nine months, which indicated that the human liver cells were proliferating in the mouse liver. In addition, when the UCSF scientists examined liver tissue from these mice under the microscope, they found the transplanted human liver cells had fully matured, making them indistinguishable from normal human liver cells.
But there’s still much more to be done before we can even think about testing iMPC-derived liver cells for therapy. The researchers’ next hurdles are to figure out how to speed the maturation time for lab-grown liver cells, as well as how to modify their procedure so that the reprogramming can be done without using viruses, which carry a potential risk of cancer.
 Mouse liver repopulation with hepatocytes generated from human fibroblasts. Zhu S, Rezvani M, Harbell J, Mattis AN, Wolfe AR, Benet LZ, Willenbring H, Ding S. Nature. 2014 Feb 23. doi: 10.1038/nature13020. [Epub ahead of print]
Holger Willenbring, Division of Transplant Surgery, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research and Liver Center, University of California San Francisco
Sheng Ding, Gladstone Institutes, San Francisco, CA
NIH support: National Institute of Diabetes and Digestive and Kidney Diseases
- Click to share on Google+ (Opens in new window)
- Click to share on Pinterest (Opens in new window)
- Click to email this to a friend (Opens in new window)
- Click to print (Opens in new window)
- Click to share on Tumblr (Opens in new window)
- Click to share on Reddit (Opens in new window)
- Click to share on Pocket (Opens in new window)
- Click to share on Telegram (Opens in new window)
- Click to share on WhatsApp (Opens in new window)
- Click to share on Skype (Opens in new window)
Posted In: Science